ENDRA Life Sciences Reports 2020 Fourth Quarter and Full Year Financial Results, Provides Business Update
ENDRA Life Sciences (NASDAQ:NDRA) reported its financial results for Q4 and FY 2020, with a net loss of $2.3 million ($0.10/share) in Q4, down from $4.8 million in 2019. Total operating expenses decreased to $2.3 million from $3.1 million in Q4 2019. For the full year, net loss was $11.7 million ($0.63/share), improved from $13.3 million in 2019. The company secured partnerships and clinical studies in Europe, strengthened its intellectual property, and raised $18.5 million through stock sales. A call to discuss results was scheduled for 4:30 PM ET today.
- Partnership with Hepion Pharmaceuticals to enhance TAEUS technology in clinical settings.
- New clinical study partnerships, expanding presence in Europe.
- Intellectual property portfolio increased to 82 global assets.
- Strengthened balance sheet with an $18.5 million capital raise.
- Operating expenses increased to $11.5 million in 2020 from $10.8 million in 2019.
- Despite revenue growth potential, the company still incurred a significant net loss of $11.7 million.
Conference call begins at 4:30 p.m. Eastern time today
ANN ARBOR, MI / ACCESSWIRE / March 25, 2021 / ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three and twelve months ended December 31, 2020 and provided a business update. Highlights of the fourth quarter of 2020 and recent weeks include the following:
- Partnered with Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical-stage biopharmaceutical company focused on AI-driven therapeutic drug development for the treatment of NASH and liver disease. ENDRA signed a collaboration agreement with Hepion to incorporate TAEUS as an add-on technology to support Hepion's patient screening and biomarker measurement during its upcoming Phase 2b study of CRV431.
- Secured a new clinical study partnership with Inselspital University Hospital in Bern, Switzerland. This is the third clinical research partnership for ENDRA in Europe and the sixth globally. The data from the Inselspital Bern study, along with other ongoing or to-be-initiated studies, will be used to bolster clinical evidence and further establish the clinical utility of the TAEUS device for assessing Non-Alcoholic Fatty Liver Disease (NAFLD).
- Began screening patients for real-world clinical validation. The first patient in a clinical study by an ENDRA clinical research partner took place at Rocky Vista University College of Osteopathic Medicine ("RVUCOM"). The TAEUS system was installed at RVUCOM's Ivins, Utah location in November 2020 with the first patient of a targeted 200, scanned in February 2021.
- Strengthened TAEUS intellectual property protection with issuance of two additional U.S. and one Chinese patents. ENDRA's intellectual property portfolio continues to grow and currently stands at 82 global assets, defined as patents issued, filed, licensed or in preparation.
- Extended collaboration agreement with GE Healthcare for two additional years. GE Healthcare will continue to support ENDRA's commercialization activities for its TAEUS technology for use in a fatty liver application by, among other things, facilitating introductions to GE Healthcare clinical ultrasound customers worldwide.
- Strengthened balance sheet with receipt of
$18.5 million from the sale of common stock. As previously announced on December 18, 2020, the Company sold 7.9 million shares of common stock for gross proceeds of$5.5 million . Subsequent to the year end, the Company has raised an additional$10.1 million from its at-the-market ("ATM") offering via the sale of 3.9 million shares at a weighted average cost of$2.58 per share, and$2.9 million from the cash exercise of approximately 3.6 million warrants. - Executed first distribution agreement for TAEUS. Quang Phat Technology Science Equipment Co. Ltd, signed an exclusive distribution agreement for the initial sale of up to 40 TAEUS liver systems in Vietnam. Sales are expected to begin as soon as TAEUS receives U.S. Food and Drug Administration (FDA) clearance and local regulatory approvals.
"Despite the challenges related to COVID-19 we faced throughout most of 2020, I am delighted with the progress the ENDRA team made to advance our commercialization strategy for the TAEUS system. We finished the year strong and are doing everything within our control to prepare for success when the healthcare system resumes services at pre-pandemic levels. This includes actively communicating with the FDA regarding our 510(k) submission in preparation for the potential clearance to begin commercialization in the U.S.," stated Francois Michelon, Chairman and Chief Executive Officer of ENDRA. "At the same time, we remain focused on gathering additional data to bolster TAEUS' clinical utility to assess and monitor chronic liver conditions. While unrelated to our FDA application, we believe these independent evaluations will assist our future commercialization efforts by documenting TAEUS' clinical and economic value versus MRI."
Renaud Maloberti, Chief Commercial Officer, added, "As we experience an improving environment with the easing of restrictions as COVID-19 cases decrease globally, our clinical study partners are enthusiastic to move forward with their TAEUS evaluations, a key part of our launch strategy. In parallel, we are building our European sales team, members of which are collaborating with GE Healthcare and engaging with clinicians via Zoom. We believe ENDRA is poised to begin reporting commercial sales in 2021 as we address this significant market opportunity with a differentiated product and compelling benefits to physicians, patients and healthcare systems."
Fourth Quarter 2020 Financial Results
- Operating expenses decreased to
$2.3 million in the fourth quarter of 2020, down from$3.1 million in the same period in 2019. The decrease was primarily due to expenses related to the development of TAEUS as the product was substantially completed and ready for sale. - Net loss in the fourth quarter of 2020 was
$2.3 million , or ($0.10) per share, compared with a net loss of$4.8 million in the fourth quarter of 2019.
Full Year 2020 Financial Results
- Operating expenses increased to
$11.5 million in 2020, up from$10.8 million in 2019. The increase in general and administration expenses and sales and marketing, was partially offset by decreased spending in research and development. - Net loss in 2020 was
$11.7 million , or ($0.63) per share, compared with a net loss of$13.3 million , or ($2.34) per share, in 2019. - Cash was provided through the sale of common stock for proceeds totaling
$6.8 million and the exercise of warrants for proceeds totaling$4.7 million during 2020. - The Company had cash and cash equivalents of
$7.2 million as of December 31, 2020, compared with$6.2 million as of December 31, 2019, with no long-term debt. - Subsequent to December 31, 2020, the Company has received exercise notices for 3.6 million warrants resulting in additional cash proceeds of
$2.9 million , as well sold approximately 3.9 million shares through its ATM facility with Ascendiant Capital for gross proceeds of$10.1 million .
Conference Call and Webcast
Management will host a conference call and webcast today at 4:30 p.m. Eastern time to discuss these results, provide an update on recent corporate developments and answer questions.
Dial-in Numbers
U.S./Canada: 888-506-0062
International: 973-528-0011
Replay Dial-in Numbers
U.S./Canada: 877-481-4010
International: 919-882-2331
Replay Passcode: 40227
The telephone replay will be available through 4:30 p.m. Eastern time on April 1, 2021
A live audio webcast will be available through the Events & Presentations page of the Investors section of the company's website at www.endrainc.com. A replay of the webcast will be available on the website for 90 days.
About ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc. is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology that mirrors some applications similar to CT or MRI, but at 50x lower cost and at the point of patient care. TAEUS® is designed to work in concert with one million ultrasound systems in global use today. TAEUS® is initially focused on the measurement of fat in the liver, as a means to assess and monitor NAFLD and NASH, chronic liver conditions that affect over 1 billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS®, including visualization of tissue temperature during energy-based surgical procedures.www.endrainc.com.
Forward-Looking Statements
All statements in this release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "goal," "estimate," "anticipate" or other comparable terms. Examples of forward-looking statements include, among others, estimates of the timing of future events and achievements, such as the expectations regarding milestones and future sales, our 510(k) submission with the FDA and commercializing the TAEUS® device; and expectations concerning ENDRA's business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including, among others, our ability to develop a commercially feasible technology; receipt of necessary regulatory approvals; the impact of COVID-19 on our business plans; our ability to find and maintain development partners, market acceptance of our technology, the amount and nature of competition in our industry; our ability to protect our intellectual property; and the other risks and uncertainties described in ENDRA's filings with the Securities and Exchange Commission. The forward-looking statements made in this release speak only as of the date of this release, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.
Company Contact:
David Wells
Chief Financial Officer
(734) 997-0464
investors@endrainc.com
www.endrainc.com
Investor Relations Contact:
Yvonne Briggs
LHA Investor Relations
(310) 691-7100
ybriggs@lhai.com
ENDRA Life Sciences Inc.
Balance Sheets
| December 31, | December 31, | |||||||
Assets | 2020 | 2019 | ||||||
Current Assets | ||||||||
Cash | $ | 7,227,316 | $ | 6,174,207 | ||||
Prepaid expenses | 390,800 | 116,749 | ||||||
Inventory | 589,620 | 113,442 | ||||||
Other current assets | 5,986 | 130,701 | ||||||
Total Current Assets | 8,213,722 | 6,535,099 | ||||||
Non-Current Assets | ||||||||
Fixed assets, net | 212,242 | 236,251 | ||||||
Right of use assets | 339,012 | 404,919 | ||||||
Total Assets | $ | 8,764,976 | $ | 7,176,269 | ||||
Liabilities and Stockholders' Equity | ||||||||
Current Liabilities | ||||||||
Accounts payable and accrued liabilities | $ | 910,183 | $ | 1,708,525 | ||||
Convertible notes payable, net of discount | - | 298,069 | ||||||
Lease liabilities, current portion | 76,480 | 66,193 | ||||||
Total Current Liabilities | 986,663 | 2,072,787 | ||||||
Long Term Debt | ||||||||
Loans | 337,084 | - | ||||||
Lease liabilities | 271,908 | 342,812 | ||||||
Total Long Term Debt | 608,992 | 342,812 | ||||||
Total Liabilities | 1,595,655 | 2,415,599 | ||||||
Stockholders' Equity | ||||||||
Preferred stock series A, | 1 | 1 | ||||||
Preferred stock series B, | - | - | ||||||
Common stock, | 3,404 | 842 | ||||||
Additional paid in capital | 64,488,558 | 49,933,736 | ||||||
Stock payable | 15,847 | 43,528 | ||||||
Accumulated deficit | (57,338,489 | ) | (45,217,437 | ) | ||||
Total Stockholders' Equity | 7,169,321 | 4,760,670 | ||||||
Total Liabilities and Stockholders' Equity | $ | 8,764,976 | $ | 7,176,269 | ||||
ENDRA Life Sciences Inc.
Statements of Operations
| Year Ended | Year Ended | |||||||
| December 31, | December 31, | |||||||
| 2020 | 2019 | |||||||
Operating Expenses | ||||||||
Research and development | $ | 5,917,944 | $ | 6,574,999 | ||||
Sales and marketing | 581,893 | 412,434 | ||||||
General and administrative | 5,002,080 | 3,856,159 | ||||||
Total operating expenses | 11,501,917 | 10,843,592 | ||||||
Operating loss | (11,501,917) | (10,843,592) | ||||||
Other Expenses | ||||||||
Amortization of debt discount | (232,426) | (2,355,469) | ||||||
Other income (expense) | 8,842 | (106,903) | ||||||
Total other expenses | (223,584) | (2,462,372) | ||||||
Loss from operations before income taxes | (11,725,501) | (13,305,964) | ||||||
Provision for income taxes | - | - | ||||||
Net Loss | $ | (11,725,501) | $ | (13,305,964) | ||||
Fair value adjustment related to warrants repricing | (395,551) | - | ||||||
Deemed dividend related to preferred stock | - | (4,219,777) | ||||||
Net Loss attributable to common stockholders | $ | (12,121,052) | $ | (17,525,741) | ||||
Net loss per share - basic and diluted | $ | (0.63) | $ | (2.34) | ||||
Weighted average common shares - basic and diluted | 19,192,226 | 7,499,984 | ||||||
ENDRA Life Sciences Inc.
Statement of Cash Flows
| Year Ended | Year Ended | |||||||
| December 31, | December 31, | |||||||
| 2020 | 2019 | |||||||
Cash Flows from Operating Activities | ||||||||
Net loss | $ | (11,725,501) | $ | (13,305,964) | ||||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Depreciation and amortization | 99,342 | 80,577 | ||||||
Common stock, options and warrants issued for services | 2,102,353 | 1,399,547 | ||||||
Amortization of debt discount | 232,426 | 2,355,469 | ||||||
Impairment of other assets | - | 249,256 | ||||||
Amortization of right of use assets | 65,907 | 34,434 | ||||||
Changes in operating assets and liabilities: | ||||||||
Increase in prepaid expenses | (274,051) | 28,675 | ||||||
Decrease in lease liability | (60,617) | (30,348) | ||||||
Increase in inventory | (476,178) | (53,998) | ||||||
Decrease in Other Current Assets | 124,715 | (106,642) | ||||||
Decrease in accounts payable and accrued liabilities | (858,991) | 760,143 | ||||||
Net cash used in operating activities | (10,770,595) | (8,588,851) | ||||||
Cash Flows from Investing Activities | ||||||||
Purchases of fixed assets | (51,333) | (43,595) | ||||||
Net cash used in investing activities | (51,333) | (43,595) | ||||||
Cash Flows from Financing Activities | ||||||||
Proceeds from senior secured convertible promissory notes, net of fees | - | 2,490,501 | ||||||
Proceeds from issuance of Series A Convertible Preferred Stock | - | 5,344,257 | ||||||
Proceeds from issuance of Series B Convertible Preferred Stock | - | 375,520 | ||||||
Proceeds from warrant exercise | 4,757,011 | - | ||||||
Proceeds from loans | 337,084 | - | ||||||
Proceeds from issuance of common stock | 6,780,942 | 125,000 | ||||||
Net cash provided by financing activities | 11,875,037 | 8,335,278 | ||||||
Net decrease in cash | 1,053,109 | (297,168) | ||||||
Cash, beginning of period | 6,174,207 | 6,471,375 | ||||||
Cash, end of period | $ | 7,227,316 | $ | 6,174,207 | ||||
Supplemental disclosures of cash items | ||||||||
Interest paid | $ | 1,920 | $ | - | ||||
Income tax paid | $ | - | $ | - | ||||
Supplemental disclosures of non-cash items | ||||||||
Discount on convertible notes | $ | - | $ | 2,490,501 | ||||
Conversion of convertible notes and accrued interest | $ | 493,814 | $ | 140,406 | ||||
Exchange of balance in convertible notes and accrued interest for Series A preferred stock | $ | - | $ | 1,943,195 | ||||
Deemed dividend | $ | 395,551 | $ | 4,219,777 | ||||
Conversion of Series A Convertible Preferred Stock | $ | (717) | $ | - | ||||
Conversion of Series B Convertible Preferred Stock | $ | (36) | $ | - | ||||
Stock dividend payable | $ | (49,649) | $ | - | ||||
Right of use asset | $ | 339,012 | $ | 404,919 | ||||
Lease liability | $ | 348,388 | $ | 409,005 | ||||
SOURCE: ENDRA Life Sciences Inc.
View source version on accesswire.com:
https://www.accesswire.com/637486/ENDRA-Life-Sciences-Reports-2020-Fourth-Quarter-and-Full-Year-Financial-Results-Provides-Business-Update
FAQ
What were ENDRA's financial results for Q4 2020?
How did ENDRA perform financially in the full year 2020?
What partnerships did ENDRA announce in March 2021?
What is the current status of ENDRA's clinical trials?
